Product Name |
Acalabrutinib-d3 |
Alternate Names |
Acalabrutinib Stable Isotopes, Stable Isotopes of Acalabrutinib |
CAT No. |
CS-T-94747
|
CAS No. |
1420477-60-6(Unlabelled) |
Category |
Stable Isotopes |
Stock |
Enquire
|
Mol. Wt. |
468.54 g/mol |
Mol. For. |
C26H20D3N7O2
|
Hazardous |
This is not a Hazardous Compound
|
COA |
View Sample COA
|
MSDS |
View Sample MSDS
|
Parent API |
Acalabrutinib |
Controlled |
No |
Shipping |
Free for purchase above 1000$ |
Delivery |
In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
Return |
Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
Ordering |
Place your order online or by email sales@clearsynth.com |
If you find a better price anywhere else we guarantee Price match.
Acalabrutinib-d3 is a deuterium-labeled derivative of Acalabrutinib, which is a Bruton’s tyrosine kinase (BTK) inhibitor used in the treatment of certain types of cancers, such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Specifically, Acalabrutinib-d3 is used as an internal standard for the quantification of Acalabrutinib in biological samples using mass spectrometry.
Chemically, Acalabrutinib-d3 has the same molecular formula as Acalabrutinib (C26H23N7O2S), except that three hydrogen atoms in the molecule have been replaced with deuterium atoms. This labeling results in a mass shift of three atomic mass units, allowing for accurate and precise quantification of Acalabrutinib in biological matrices.
In terms of usage, Acalabrutinib-d3 is typically used in pharmacokinetic studies to determine the drug’s absorption, distribution, metabolism, and excretion (ADME) properties in humans and animals. It is also used in drug-drug interaction studies to assess the potential for Acalabrutinib to interact with other drugs and affect their ADME properties.
Overall, Acalabrutinib-d3 is a valuable tool for researchers and clinicians in the development and optimization of Acalabrutinib-based therapies for the treatment of cancer. Its chemical properties and usage in pharmacokinetic studies ensure the safe and effective use of Acalabrutinib in clinical practice.